BSTC BioSpecifics Technologies Corp

63.19
-0.56  -1%
Previous Close 63.75
Open 63.59
Price To Book 4.72
Market Cap 460459337
Shares 7,286,902
Volume 82,267
Short Ratio
Av. Daily Volume 48,468

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Endo is currently performing a commercial assessment.
XIAFLEX
Plantar fibromatosis
Phase 2 topline data released June 2016 - endpoints met
XIAFLEX
Human lipomas
BLA filing 2H 2019.
XIAFLEX (collagenase clostridium histolyticum) - RELEASE
Edematous fibrosclerotic panniculopathy (“cellulite”)
Phase 2b trial did not meet endpoint. Endo is currently performing a commercial assessment.
XIAFLEX
Adhesive Capsulitis (“Frozen Shoulder syndrome”)
Phase 1 data released October 31, 2018 - primary endpoint of safety and tolerability met.
XIAFLEX
Uterine fibroids

Latest News

  1. Achaogen (AKAO) Files for Bankruptcy, Shares Plunge 65%
  2. Weekly Jobless Claims Lowest in Nearly 50 Years: 5 Top Picks
  3. Zogenix Gets Refusal to File Letter From FDA for Seizure Drug
  4. United Therapeutics Discontinues PAH Drug After Study Fails
  5. 3 Reasons Why BioSpecifics (BSTC) Is a Great Growth Stock
  6. 5 Stocks With Recent Price Strength Despite Market Volatility
  7. BioSpecifics: 4Q Earnings Snapshot
  8. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2018 Financial Results
  9. Zacks.com featured expert Kevin Matras highlights: Darden Restaurants, Best Buy, BioSpecifics Technologies and ONEOK
  10. 4 Top Stocks to Buy for Superb Earnings Growth
  11. BioSpecifics (BSTC) Upgraded to Strong Buy: Here's What You Should Know
  12. BioSpecifics Technologies Corp. Announces Passing of President Thomas L. Wegman
  13. What's in Store for BioSpecifics (BSTC) This Earnings Season?
  14. Is BioSpecifics Technologies Corp. (NASDAQ:BSTC) A Volatile Stock?
  15. Analysis: Positioning to Benefit within Amarin, Retrophin, Sunrun, BioSpecifics Technologies, Arbutus Biopharma, and TOCAGEN INC — Research Highlights Growth, Revenue, and Consolidated Results
  16. BioSpecifics (BSTC) Upgraded to Buy: Here's What You Should Know
  17. Is BioSpecifics Technologies (BSTC) Stock Outpacing Its Medical Peers This Year?
  18. Is BioSpecifics Technologies Corp.’s (NASDAQ:BSTC) Balance Sheet Strong Enough To Weather A Storm?
  19. Ocular (OCUL) Submits an sNDA for Eye Pain Drug Dextenza
  20. INSYS Therapeutics Rises on Dose-Ranging Allergy Study Data